|
|
Volumn 68, Issue 3, 2008, Pages 496-502
|
|
Approval of new biopharmaceuticals 1999-2006: Comparison of the US, EU and Japan situations
|
|
Author keywords
Biopharmaceuticals; Drug approval; Drug lag; Three regions (US, EU, Japan)
|
|
Indexed keywords
ALEMTUZUMAB;
BASILIXIMAB;
BECAPLERMIN;
BETA1A INTERFERON;
CHORIONIC GONADOTROPIN ALPHA SUBUNIT;
DACLIZUMAB;
ETANERCEPT;
GEMTUZUMAB OZOGAMICIN;
IBRITUMOMAB TIUXETAN;
INFLIXIMAB;
INSULIN ASPART;
INSULIN GLARGINE;
INSULIN LISPRO;
INTERFERON BETA SERINE;
NESIRITIDE;
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
PALIVIZUMAB;
PARATHYROID HORMONE[1-34];
PEGINTERFERON ALPHA2B;
RASBURICASE;
RECOMBINANT BLOOD CLOTTING FACTOR 7A;
RECOMBINANT BLOOD CLOTTING FACTOR 8;
RECOMBINANT FOLLITROPIN;
RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
RETEPLASE;
RITUXIMAB;
TENECTEPLASE;
TRASTUZUMAB;
UNINDEXED DRUG;
ANALYTIC METHOD;
ARTICLE;
DRUG APPROVAL;
DRUG INDICATION;
DRUG MANUFACTURE;
DRUG MARKETING;
EUROPE;
JAPAN;
LICENSING;
UNITED STATES;
BIOLOGICAL PRODUCTS;
DRUG APPROVAL;
EUROPEAN UNION;
JAPAN;
TIME FACTORS;
UNITED STATES;
|
|
EID: 39849104302
PISSN: 09396411
EISSN: None
Source Type: Journal
DOI: 10.1016/j.ejpb.2007.07.013 Document Type: Article |
|
Times cited : (26)
|
|
References (12)
|
